Rocket Lab's Defense Hype Obscures Neutron Delays and Cash Burn Concerns

What happened

Rocket Lab announced Q4 2025 results with 16% sequential sales growth and a $1.85 billion backlog, heavily weighted towards government contracts, underscoring its pivot to defense work. However, the Neutron rocket's first launch has been delayed to Q4 2026 after a Stage 1 tank rupture, which management blames on a third-party manufacturing defect but claims is fixable with automated processes. The DeepValue report highlights that this delay is not isolated, increasing execution risk and potential for further slips if qualification failures recur, as seen in early 2026. Despite the bullish narrative, the company remains deeply loss-making with negative cash flow and a history of ATM equity issuance, raising dilution fears amid high valuation multiples. Insider selling in early 2026, including clustered sales by the CFO and directors, adds to skepticism about near-term confidence and contrasts with public optimism.

Implication

Rocket Lab's stock is priced for perfection, assuming timely Neutron deployment and defense contract conversion, but any further delays could trigger significant downside given the crowded narrative and high execution risk. The SDA Tranche 3 award, while a long-term positive, has launches scheduled for FY2029, limiting near-term revenue impact and requiring investors to scrutinize milestone billing for 2026-2027 economic bridges. Persistent cash burn, negative earnings, and historical ATM issuance heighten financial vulnerability, with dilution likely if development costs persist without improved profitability. Insider selling patterns, including multi-tranche sales by key executives, signal reduced internal confidence that investors should weigh against promotional rhetoric. Therefore, a disciplined approach with entry points below $55 is advisable to mitigate risks, aligning with the DeepValue report's 'POTENTIAL SELL' rating until observable progress emerges.

Thesis delta

The Seeking Alpha article's optimistic spin on manageable Neutron delays and defense opportunities does not shift the core investment thesis, which remains anchored in execution risks and weak fundamentals. No new positive catalysts have emerged; instead, the narrative reinforces the need for proof points on Neutron qualification and SDA milestone billing in the next 6-9 months, as outlined in the DeepValue report. Investors should remain skeptical and consider trimming or avoiding positions unless these indicators materialize to reduce downside exposure.